Therapeutically targeting Carbonic Anhydrase IX (CAIX) in hypoxic solid tumors with the small-molecule inhibitor SLC-0111 has shown significant inhibition of tumor growth and metastasis in preclinical models of breast and brain cancer [287–289]. This evidence concerns the gene CA9 and neoplasm.